A rising stock price is the cure for any investor’s glum mood. Sorrento Therapeutics (SRNE 7.29%) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company’s coronavirus drug candidate.
That morning, Sorrento reported that it has reached full enrollment for its phase 1 study of that drug, Covishield. All told, 24 healthy recipients will be administered the drug, in the form of a…
>>>read full article here<<<